Announced Fri, 14 Nov · 17:40 IST

Intimation of the additional capacity installation at the new manufacturing unit (Unit-II) of Asston Pharmaceuticals Limited.

Capex & Operations View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Asston Pharmaceuticals is setting up a second manufacturing unit (Unit-II) at MIDC, Additional Ambernath, Thane, for producing pharmaceuticals and nutraceuticals. The new unit will take total capacity from 5-6 crore tablets/month to 14-15 crore tablets/month, nearly 2.5-3x the current capacity which is already running at 80% utilisation. The project involves an investment of approximately ₹6 crore, to be funded through internal accruals and IPO proceeds, and is targeted for completion by Q4 FY26. The company says the expansion is needed to meet captive requirements and growing market demand.

Likely market impact

Positive for long-term growth as the company significantly scales up production capacity to capture rising demand, though investors should watch for execution timelines and any margin pressure during the ramp-up phase.